Metastatic cutaneous apocrine adenocarcinoma successfully treated with systemic anti‐androgen therapy—A case report

Primary cutaneous apocrine adenocarcinoma (PCAC) is an extremely rare neoplasm involving the sweat glands. Due to a lack of cases, there is no consensus for the systemic treatment of locally advanced or metastatic PCAC. Anti‐androgen therapy may have activity in inoperable or metastatic PCAC with high androgen receptor (AR) expression.

[1]  A. Villers,et al.  ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Peter Schmid,et al.  Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Croxatto,et al.  A case report of a primary apocrine adenocarcinoma of the eyelid with literature review , 2018, Orbit.

[4]  I. Zalaudek,et al.  Metastatic cutaneous apocrine adenocarcinoma responsive to the programmed cell death protein 1 inhibitor pembrolizumab. , 2017, European journal of cancer.

[5]  J. Brewer,et al.  Apocrine Axillary Adenocarcinoma: An Aggressive Adnexal Tumor in Middle-Age Individuals. , 2017, Dermatologic Surgery.

[6]  C. Barker,et al.  Metastatic cutaneous apocrine carcinoma: Multidisciplinary approach achieving complete response with adjuvant chemoradiation , 2017, JAAD case reports.

[7]  S. Aiba,et al.  Successful Treatment of Advanced Primary Cutaneous Apocrine Carcinoma on the Scrotum with Systemic Chemotherapy and Radiotherapy Followed by Denosumab , 2017, Case Reports in Oncology.

[8]  G. Kao,et al.  Cutaneous adnexal carcinoma with apocrine differentiation. , 2016, Cutis.

[9]  B. Lew,et al.  Primary Cutaneous Apocrine Carcinoma , 2016, Annals of dermatology.

[10]  P. Zoroquiaín,et al.  Apocrine adenocarcinoma of the eyelid. , 2016, International journal of ophthalmology.

[11]  J. Grenier,et al.  A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Riesco-Martinez,et al.  Treatment of primary cutaneous apocrine carcinoma of the scalp - case and review of the literature , 2016 .

[13]  T. Shien,et al.  Metastatic Cutaneous Apocrine Adenocarcinoma Treated With a Combination of Pertuzumab-Based Targeted Therapy and Taxane Chemotherapy: A Case Report. , 2016, JAMA dermatology.

[14]  J. Cardoso,et al.  Malignant sweat gland tumours: an update , 2015, Histopathology.

[15]  R. Joseph,et al.  Management of Metastatic Apocrine Hidradenocarcinoma with Chemotherapy and Radiation , 2015, Rare tumors.

[16]  T. Brenn.  Malignant Sweat Gland Tumors: An Update , 2015, Advances in anatomic pathology.

[17]  I. Choi,et al.  Large cutaneous apocrine carcinoma occurring on right thigh aggravated after moxa treatment , 2015, Annals of surgical treatment and research.

[18]  Jinhua Xu,et al.  Cutaneous apocrine carcinoma in groin with bilateral lymph node metastasis: a case report and review of the literature. , 2014, International journal of clinical and experimental pathology.

[19]  Y. Fujisawa,et al.  Metastatic cutaneous apocrine carcinoma of the axilla successfully treated using systemic chemotherapy with i.v. epirubicin and cyclophosphamide followed by oral fluorinated pyrimidine , 2014, The Journal of dermatology.

[20]  T. Gudewicz,et al.  Cutaneous and mammary apocrine carcinomas have different immunoprofiles. , 2014, Human pathology.

[21]  M. Kasami,et al.  Treatment strategy for cutaneous apocrine carcinoma , 2014, International Journal of Clinical Oncology.

[22]  Andres Forero,et al.  Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer , 2013, Clinical Cancer Research.

[23]  M. Mizuashi,et al.  Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine. , 2012, Acta dermato-venereologica.

[24]  T. Fitzgerald,et al.  Cutaneous apocrine adenocarcinoma: Defining epidemiology, outcomes, and optimal therapy for a rare neoplasm , 2012, Journal of surgical oncology.

[25]  S. Toda,et al.  Histiocytoid and signet‐ring cell carcinoma of the axilla: a type of cutaneous apocrine carcinoma equivalent to histiocytoid lobular carcinoma of the breast? , 2011, Clinical and experimental dermatology.

[26]  E. Moustou,et al.  Primary Cutaneous Apocrine Carcinoma of Sweat Glands: A Rare Case Report , 2011, Case Reports in Oncology.

[27]  A. Fernandez-Flores.  Primary cutaneous apocrine carcinoma versus metastasis, a plea to the dermatopathology community. , 2010, The American Journal of dermatopathology.

[28]  M. Feinmesser,et al.  Primary Cutaneous Apocrine Carcinoma: A Clinico-pathologic Analysis of 24 Cases , 2008, The American journal of surgical pathology.

[29]  K. Korski,et al.  Metastatic apocrine adenocarcinoma of the axillary area , 2006 .

[30]  P. Woll,et al.  Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. White,et al.  Apocrine gland carcinoma of the axilla: review of the literature and recommendations for treatment. , 1999, American journal of clinical oncology.